In an effort to promote its latest ventilation and respiratory
) unveiled several new products at the American Association for
Respiratory Care (AARC) Congress. Some of the new devices that
were on display included the Ventilator Associated Event (VAE)
application, AirLife Misty Fast disposable small-volume nebulizer
(SVN), Vmax Vyntus SPIRO and the LTV Series ventilators.
CAREFUSION CORP (CFN): Free Stock Analysis
HILL-ROM HLDGS (HRC): Free Stock Analysis
MEDTRONIC (MDT): Free Stock Analysis Report
NUVASIVE INC (NUVA): Free Stock Analysis
To read this article on Zacks.com click here.
The company's shares had slipped slightly after reporting
flattish fiscal 2014 first-quarter results on Nov 8. However,
immediately thereafter CFN's shares picked up pace and is
currently trading at $38.73 as of Nov 19. However, these product
launches (announced on Nov 15) failed to create any significant
impact on the share price.
The VAE technology on the CareFusion Knowledge Portal is capable
of providing vital information to doctors regarding near-real
time patient conditions. It is also equipped to identify whether
the patient is at a risk of developing a ventilator-associated
condition. This significantly helps to improve patient outcome
along with clinical efficiency.
The new AirLife Misty Fast SVN and the AirLife manual
self-inflating resuscitation devices II were also displayed at
the AARC Congress. According to a study, the AirLife Misty Fast
SVN can deliver efficacious drugs (drugs within respirable range
of one to five microns) much faster than four other SVNs tested
CareFusion's latest Vmax Vyntus SPIRO is used for pulmonary
function testing. Additionally, the company also intends to
conduct a workshop on CFN's LTV Series ventilators at the event.
The light-weight and uncomplicated design of the LTV Ventilator
allows for easy mobility in emergency situations that require
critical care invasive and non-invasive ventilation.
CareFusion is a global corporation serving the health care
industry with products and services that help hospitals to
measurably improve standards of care. We believe that the company
will be able to garner significant revenues from its latest
offerings in the ventilation and respiratory portfolio.
Currently, CareFusion has a Zacks Rank #3 (Hold). However, stocks
that are performing relatively better in the medical products
Hill-Rom Holdings, Inc.
). HRC and NUVA carry a Zacks Rank #1 (Strong Buy), while MDT
sports a Zacks Rank #2 (Buy).